Novartis partner Artios bags megaround to drive clinical work on DNA damage repair factors

Kyle Blankenship

Biopharma is constantly on the hunt for the next generation of targeted oncology drugs to effectively wipe out cancer cells. But to keep those tumors …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Novartis partner Artios bags megaround to drive clinical work on DNA damage repair factors

Kyle Blankenship

Sign up to read this article for free.

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

Biohaven stock sinks on three-month delay for neuro drug's FDA approval decision

Merck KGaA will continue to add a tariff surcharge for US customers

Hengrui, one of China's leading biotechs, anticipates $1.2B in proposed Hong Kong listing

FDA gives AbbVie accelerated approval for antibody-drug conjugate in lung cancer

Sanofi touts $20B investment in US over five years

GSK to pay $1.2B upfront to snag Boston Pharma’s mid-stage MASH hope

No­var­tis part­ner Ar­tios bags megaround to dri­ve clin­i­cal work on DNA dam­age re­pair fac­tors

Sign up to read this article for free.

more like this

ImmunityBio, Inc.

Remote

Novartis partner Artios bags megaround to drive clinical work on DNA damage repair factors